Henlius Sets 2026 AGM to Approve 2025 Results and New Share Issuance Mandate

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an announcement.

Shanghai Henlius Biotech, Inc. has called its annual general meeting for 19 May 2026 in Shanghai, where shareholders will review the company’s 2025 performance, including the annual report, board and supervisory board work reports, final accounts, profit distribution proposal and executive director remuneration. Investors will also vote on the re-appointment of Ernst & Young Hua Ming as domestic auditor and Ernst & Young as international auditor, ensuring continuity in financial oversight for 2026.

The meeting will further consider a special resolution to grant the board a broad share issuance mandate of up to 20% of the company’s share capital, including the power to issue convertible bonds, warrants and other equity-linked instruments without further general meeting approval. This authority, if passed, would give Henlius greater flexibility to raise capital and pursue funding or strategic initiatives, with potential implications for future dilution and the company’s capital structure.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, specializing in the research, development and commercialization of biologic drugs. Listed in Hong Kong, the company operates through a group structure and focuses on advancing its pipeline and marketed products in both domestic and international markets.

Average Trading Volume: 1,201,679

Technical Sentiment Signal: Buy

Current Market Cap: HK$43.07B

See more data about 2696 stock on TipRanks’ Stock Analysis page.